Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For sure MADD! These products are actually pretty wild, super cutting edge, I've followed the space for a minute... And this is a really unique line. Will be really interesting to see how this whole thing develops. I think VANC could be a big player if they make good strategic moves.
Sweet thanks for clarification !!
Ready for updates , this one going be fun !!!
Was already announced 2 prs ago
CBD products would definitely be a good addition here, are they working on that?
Ready hear about cbd sales ??$?$! Hopefully 250k worth
Yes sir. Might take a little time to get this up to full steam, but there's no telling what kind of leaps the pps will take on the way to profitability. $NUVPF
Agreed, market cap is so tiny right now. I cant wait to see if Canadian provinces start approving pharmacies. Makes sense to me. Hopefully common sense prevails, becaues VANC is perfectly positioned for it.... GLTU
Wish I could afford to buy more. Should be fun as the sector ramps up into legalization and beyond.
Whoever bought up 1M+ shares two weeks ago knows this is going up imo
No selling down here, shares dried up, NUVPF going to be explosive off these levels sooner or later. Summer is already almost here. Legalization is coming in Canada soon enough.
No rush here just the very beginning
Yes sir! A little news and some volume will go a long way here. $NUVPF
This is about to change fast if any provinces approve pharmacies.
Big sector news today ... let’s gooooo
Emerald Health Therapeutics Expands Strategic Investment in VANC
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) announced today that it has entered into a supply and distribution agreement (“Distribution Agreement”) with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”), pursuant to which VANC was granted rights to sell and distribute certain proprietary endocannabinoid-supporting products in Canada to licensed pharmacies. The parties intend to set a minimum sales benchmark with respect to the sale and distribution of the products over the next 30 days on a non-exclusive basis. Concurrently, VANC entered into an arrangement with a different affiliate of Emerald, pursuant to which the parties expressed their intention to work together to distribute medical cannabis to Canadian pharmacies if pharmacies become authorized to do so by Health Canada.
https://web.tmxmoney.com/article.php?newsid=4531326892146277&qm_symbol=VANC
With NUVPF, I dont know how much of it is manipulation vs. just market dynamics, but it is definitely hard to get shares on the bid, I've had to buy above the ask recently. TSX has had some problems, they had issues a week ago last Friday toward EOD with their executions.
"I am also noticing its hard to get shares down here too unless u want tonpay above the ask. Imho"
I have noticed the same thing.
Agree brother lets get that dollar holla
I couldn't agree more. I'm betting this hits a $1+ easy with the right news and a bullish sector, and that's being conservative. $NUVPF IMHO of course.
They pull it down on light vol then snap it up, one of these days not far away we are going to see Nuvpf snap up for 100s of percent in a very quick repricing move to a more reasonable mkt cap given the potential for pharmacy market cannabis sales. I am also noticing its hard to get shares down here too unless u want tonpay above the ask. Imho
Green lets keep it up!
Looking good in here.
http://nasdaqnewsreports.blogspot.de/2018/05/buying-undervalued-weed-and-pharma.html
Ready for the cannabis news to start flowing !!!
It is going to be really interesting to watch them roll out their new strategy with point of care technologies and OTC/BTC products. The user interface of the Corozon and HealthTab platforms, combined with cannabis legalization and pharmacy distribution, could be a game changer in terms of how consumers learn about medicinal cannabis. I would imagine that these platforms will integrate cannabis related features rapidly over the coming months. Also, I would not be surprised to see further strategic acquisitions takig place in the pharmacy space. Exciting times!
When they start announcing licenses to distribute this will be in dollars ..imho
Pharmacy distribution of medical cannabis
Once it starts it will be thinnnn NUVPF
Not that it matters in the the short term...holding this one well into legalization.
Let's go VANC/NUVPF...give papa some green for the weekend. lol
The Corozon Platform, acquired in April 2018, offers a variety of functionalities including e-learning, e-commerce and potentially promotional modules. These capabilities ideally position it to serve as an anchor for this pillar of the business, functioning as an educational tool and distribution channel for a number of VANC products, including those the company will distribute for Emerald.
Mr. Rai added: “We will be able to leverage the Platform to promote our latest offerings and educate pharmacists on how to use them effectively. It will serve to drive our relationships with pharmacists and will also be a powerful retention tool. Through Corozon, we can efficiently market new services and products directly to the pharmacist.”
Marketing directly to pharmacists. :) That whole PR smells really good! Lol $NUVPF/VANC
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) Board of Directors provided guidance on future company direction and initiatives today.
“In 2017 VANC had begun to anticipate secular changes affecting the generic and community pharmacy industries,” stated Mr. Bob Rai, CEO of VANC. “These changes included the trend towards increased funded participation by pharmacists in healthcare treatment of Canadians as well as dramatically shrinking margins on generic drugs. Our recent strategic partnerships, acquisitions and key personnel changes are a direct reflection of our vision, with a clear focus on growing beyond generics to provide pharmacists with innovative, value-added products, services and information to support their evolving business models and expanding role as front-line healthcare providers,” concluded Mr. Rai.
Concurrent with VANC’s new focus, the company will be reducing its generic portfolio over the next several months. Emerging opportunities in new healthcare sectors and the diminished ability to profit from generic sales drove this strategic decision. The realignment will provide existing products and services with increased focus and resources. This will also drive the expansion of a portfolio of high-margin over the counter (OTC) and point of care (POC) testing products and services that offer unique value to pharmacists, their patients, and consumers.
VANC is expanding its portfolio with announcements of strategic partnerships with Emerald, acquisition of the Corozon Platform, and plans to increase deployment of and expand offerings associated with HealthTab.
The recently announced strategic partnership with Emerald enables VANC to compete in the emerging medical cannabis sector with a line of endocannabinoid enhancers and with the potential to distribute medical cannabis to pharmacies when that avenue of sales is legalized.
“With a renewed focus on high-margin OTC/BTC product development, in addition to our recently announced partnership with Emerald Health, we anticipate generating increased sales and profitability in this pillar of the business in 2018,” explained Mr. Rai. “This shift in focus has also allowed us to engage with sales brokers across Canada, providing greater coverage to our products.”
The Corozon Platform, acquired in April 2018, offers a variety of functionalities including e-learning, e-commerce and potentially promotional modules. These capabilities ideally position it to serve as an anchor for this pillar of the business, functioning as an educational tool and distribution channel for a number of VANC products, including those the company will distribute for Emerald.
Mr. Rai added: “We will be able to leverage the Platform to promote our latest offerings and educate pharmacists on how to use them effectively. It will serve to drive our relationships with pharmacists and will also be a powerful retention tool. Through Corozon, we can efficiently market new services and products directly to the pharmacist.”
HealthTab will form the core of VANC’s future expansion of its point of care pharmacy screening tests to empower pharmacists and improve patient health. HealthTab as it is today will provide pharmacists with a platform to integrate precise blood chemistry into billable medicine reviews for patients in a timely and convenient manner.
“Our HealthTab service is based on a unique technology initially developed to provide a lab quality yet simple test for astronauts on the International Space Station. VANC can now provide this service to the general population. It will change how patients manage their health. It will also benefit the community by serving as a simple screening tool to detect serious conditions such as kidney failure or high cholesterol,” said Mr. Rai.
HealthTab systems have already been launched with strategic community pharmacy pilot programs in BC and Ontario. Furthermore, commitments for additional deployments have been secured and are scheduled for launch in Q2 2018. Additional tests to complement those currently offered by the HealthTab framework are in development and will make it best in class in terms of scope and accessibility to patients.
“The Emerald investment and licensing and the HealthTab and Corozon Platform acquisitions represent significant first steps in repositioning VANC. Further steps are being taken to create the structure and branding that will drive the evolution of our business to a new level in 2018,” concluded Mr. Rai.
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing, and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
www.vancpharm.com
For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bob Rai, Director, and CEO
604-247-2639
info@vancpharm.com
www.vancpharm.com
NUVPF train departing soon to $1
Lookin good brother lets go! $NUVPF
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
307
|
Created
|
07/20/15
|
Type
|
Free
|
Moderators |
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) (TSXV:VANC) (OTCQB:NUVPF) Board of Directors provided guidance on future company direction and initiatives today.
“In 2017 VANC had begun to anticipate secular changes affecting the generic and community pharmacy industries,” stated Mr. Bob Rai, CEO of VANC. “These changes included the trend towards increased funded participation by pharmacists in healthcare treatment of Canadians as well as dramatically shrinking margins on generic drugs. Our recent strategic partnerships, acquisitions and key personnel changes are a direct reflection of our vision, with a clear focus on growing beyond generics to provide pharmacists with innovative, value-added products, services and information to support their evolving business models and expanding role as front-line healthcare providers,” concluded Mr. Rai.
Concurrent with VANC’s new focus, the company will be reducing its generic portfolio over the next several months. Emerging opportunities in new healthcare sectors and the diminished ability to profit from generic sales drove this strategic decision. The realignment will provide existing products and services with increased focus and resources. This will also drive the expansion of a portfolio of high-margin over the counter (OTC) and point of care (POC) testing products and services that offer unique value to pharmacists, their patients, and consumers.
VANC is expanding its portfolio with announcements of strategic partnerships with Emerald, acquisition of the Corozon Platform, and plans to increase deployment of and expand offerings associated with HealthTab.
The recently announced strategic partnership with Emerald enables VANC to compete in the emerging medical cannabis sector with a line of endocannabinoid enhancers and with the potential to distribute medical cannabis to pharmacies when that avenue of sales is legalized.
“With a renewed focus on high-margin OTC/BTC product development, in addition to our recently announced partnership with Emerald Health, we anticipate generating increased sales and profitability in this pillar of the business in 2018,” explained Mr. Rai. “This shift in focus has also allowed us to engage with sales brokers across Canada, providing greater coverage to our products.”
The Corozon Platform, acquired in April 2018, offers a variety of functionalities including e-learning, e-commerce and potentially promotional modules. These capabilities ideally position it to serve as an anchor for this pillar of the business, functioning as an educational tool and distribution channel for a number of VANC products, including those the company will distribute for Emerald.
Mr. Rai added: “We will be able to leverage the Platform to promote our latest offerings and educate pharmacists on how to use them effectively. It will serve to drive our relationships with pharmacists and will also be a powerful retention tool. Through Corozon, we can efficiently market new services and products directly to the pharmacist.”
HealthTab will form the core of VANC’s future expansion of its point of care pharmacy screening tests to empower pharmacists and improve patient health. HealthTab as it is today will provide pharmacists with a platform to integrate precise blood chemistry into billable medicine reviews for patients in a timely and convenient manner.
“Our HealthTab service is based on a unique technology initially developed to provide a lab quality yet simple test for astronauts on the International Space Station. VANC can now provide this service to the general population. It will change how patients manage their health. It will also benefit the community by serving as a simple screening tool to detect serious conditions such as kidney failure or high cholesterol,” said Mr. Rai.
HealthTab systems have already been launched with strategic community pharmacy pilot programs in BC and Ontario. Furthermore, commitments for additional deployments have been secured and are scheduled for launch in Q2 2018. Additional tests to complement those currently offered by the HealthTab framework are in development and will make it best in class in terms of scope and accessibility to patients.
“The Emerald investment and licensing and the HealthTab and Corozon Platform acquisitions represent significant first steps in repositioning VANC. Further steps are being taken to create the structure and branding that will drive the evolution of our business to a new level in 2018,” concluded Mr. Rai.
About VANC Pharmaceuticals Inc.
VANC Pharmaceuticals aims to become the partner of choice for forward-thinking pharmacies across Canada. With an established sales force, distribution network, and team of highly experienced professionals in pharmacy, point-of-care testing, and health technology, VANC is growing beyond generics to provide pharmacists with innovative, value-added products and services to expand their scope of practice and support their evolving role as front-line healthcare providers.
For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Bob Rai, Director, and CEO
604-247-2639
info@vancpharm.com
www.vancpharm.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |